Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Sep;73(3):473–478.

Measurement of terminal complement complexes in rheumatoid arthritis.

B P Morgan 1, R H Daniels 1, B D Williams 1
PMCID: PMC1541752  PMID: 3208454

Abstract

Though complement activation is recognized as a central event in inflammation in the rheumatoid joint, little attention has been paid to the role of the cytolytic membrane attack complex of complement in the pathogenesis of this disease. The membrane attack complex causes a variety of non-lethal effects in nucleated cells, including stimulation of release of inflammatory mediators, and cell proliferation. Thus in the rheumatoid synovium, non-lethal effects of complement membrane attack may play a major role in disease pathology. In order to investigate this possibility, assays for the detection of terminal complement complexes in biological fluids have been established, and used to demonstrate membrane attack pathway activation in rheumatoid arthritis. Terminal complement complexes were present in increased levels in synovial fluid (mean, 1,334 ng/ml) and plasma (mean, 513 ng/ml) in 20 patients with rheumatoid arthritis when compared with controls (mean, 285 ng/ml and 129 ng/ml respectively). Using an assay specific for the SC5b-9 complex it was demonstrated that the raised levels of terminal complement complexes in rheumatoid synovial fluid consisted of a mixture of inactive SC5b-9 complexes and fluid-phase complement membrane attack complexes.

Full text

PDF
473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraha A., Morgan B. P., Luzio J. P. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J. 1988 Apr 1;251(1):285–292. doi: 10.1042/bj2510285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bhakdi S., Roth M. Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum. J Immunol. 1981 Aug;127(2):576–580. [PubMed] [Google Scholar]
  3. Bhakdi S., Tranum-Jensen J. Molecular weight of the membrane C5b-9 complex of human complement: characterization of the terminal complex as a C5b-9 monomer. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1818–1822. doi: 10.1073/pnas.78.3.1818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Curd J. G., Sundsmo J. S., Kolb W. P., Bluestein H. G., Müller-Eberhard H. J. Neoantigen of the membrane attack complex of human complement: Occurrence on peripheral blood leukocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 1978 Mar;21(2):177–182. doi: 10.1002/art.1780210201. [DOI] [PubMed] [Google Scholar]
  5. Dankert J. R., Shiver J. W., Esser A. F. Ninth component of complement: self-aggregation and interaction with lipids. Biochemistry. 1985 May 21;24(11):2754–2762. doi: 10.1021/bi00332a024. [DOI] [PubMed] [Google Scholar]
  6. Gawryl M. S., Simon M. T., Eatman J. L., Lint T. F. An enzyme-linked immunoabsorbent assay for the quantitation of the terminal complement complex from cell membranes or in activated human sera. J Immunol Methods. 1986 Dec 24;95(2):217–225. doi: 10.1016/0022-1759(86)90409-6. [DOI] [PubMed] [Google Scholar]
  7. HEDBERG H. STUDIES ON THE DEPRESSED HEMOLYTIC COMPLEMENT ACTIVITY OF SYNOVIAL FLUID IN ADULT RHEUMATOID ARTHRITIS. Acta Rheumatol Scand. 1963;9:165–193. [PubMed] [Google Scholar]
  8. Hay F. C., Nineham L. J., Perumal R., Roitt I. M. Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features. Ann Rheum Dis. 1979 Feb;38(1):1–7. doi: 10.1136/ard.38.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hugo F., Jenne D., Bhakdi S. Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement. Biosci Rep. 1985 Aug;5(8):649–658. doi: 10.1007/BF01116996. [DOI] [PubMed] [Google Scholar]
  10. Hugo F., Krämer S., Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods. 1987 May 20;99(2):243–251. doi: 10.1016/0022-1759(87)90134-7. [DOI] [PubMed] [Google Scholar]
  11. Jose P. J. Complement-derived peptide mediators of inflammation. Br Med Bull. 1987 Apr;43(2):336–343. doi: 10.1093/oxfordjournals.bmb.a072186. [DOI] [PubMed] [Google Scholar]
  12. Mollnes T. E., Lea T., Harboe M., Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol. 1985 Aug;22(2):183–195. doi: 10.1111/j.1365-3083.1985.tb01870.x. [DOI] [PubMed] [Google Scholar]
  13. Mollnes T. E., Lea T., Mellbye O. J., Pahle J., Grand O., Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986 Jun;29(6):715–721. doi: 10.1002/art.1780290603. [DOI] [PubMed] [Google Scholar]
  14. Mollnes T. E., Paus A. Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1986 Nov;29(11):1359–1364. doi: 10.1002/art.1780291108. [DOI] [PubMed] [Google Scholar]
  15. Mollnes T. E. Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol. 1985 Jun;21(6):607–613. doi: 10.1111/j.1365-3083.1985.tb01851.x. [DOI] [PubMed] [Google Scholar]
  16. Morgan B. P., Daw R. A., Siddle K., Luzio J. P., Campbell A. K. Immunoaffinity purification of human complement component C9 using monoclonal antibodies. J Immunol Methods. 1983 Nov 25;64(3):269–281. doi: 10.1016/0022-1759(83)90434-9. [DOI] [PubMed] [Google Scholar]
  17. Peakman M., Lobo-Yeo A., Senaldi G., Nilsson M., Tee D. E., Vergani D. Quantification of C3d in biological fluids by an enzyme-linked immunosorbent assay. J Immunol Methods. 1987 Nov 23;104(1-2):51–56. doi: 10.1016/0022-1759(87)90486-8. [DOI] [PubMed] [Google Scholar]
  18. Ruddy S., Austen K. F. Activation of the complement system in rheumatoid synovitis. Fed Proc. 1973 Feb;32(2):134–137. [PubMed] [Google Scholar]
  19. Rumfeld W. R., Morgan B. P., Campbell A. K. The ninth complement component in rheumatoid arthritis, Behçet's disease and other rheumatic diseases. Br J Rheumatol. 1986 Aug;25(3):266–270. doi: 10.1093/rheumatology/25.3.266. [DOI] [PubMed] [Google Scholar]
  20. Sanders M. E., Schmetz M. A., Hammer C. H., Frank M. M., Joiner K. A. Quantitation of activation of the human terminal complement pathway by ELISA. J Immunol Methods. 1985 Dec 27;85(2):245–256. doi: 10.1016/0022-1759(85)90135-8. [DOI] [PubMed] [Google Scholar]
  21. Sheppeard H., Lea D. J., Ward D. J. Synovial fluid total hemolytic complement activity in rheumatic diseases - a reappraisal. J Rheumatol. 1981 May-Jun;8(3):390–397. [PubMed] [Google Scholar]
  22. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978 Apr 20;298(16):869–871. doi: 10.1056/NEJM197804202981602. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES